Influenza viruses cause seasonal epidemics as well as pandemics and are a significant concern for human health. Current influenza vaccines show efficacy when they are antigenically well matched to circulating strains. Seasonal influenza viruses undergo antigenic drift at a high rate and, therefore, current vaccines have to be reformulated and readministered on an annual basis. Mismatches between vaccine strains and circulating strains frequently occur, significantly decreasing vaccine efficacy. In addition, current seasonal influenza virus vaccines have limited efficacy against newly emerging pandemic viruses. A universal influenza virus vaccine that induces long-term protection against all influenza virus strains would abolish the need for annual readministration of seasonal influenza virus vaccines and would significantly enhance our pandemic preparedness.

UIV 2020 – this new forum will offer researchers an opportunity to discuss the characteristics of universal influenza vaccines, their potential target antigens, and critical aspects to consider on the path to successfully developing such universal influenza virus vaccines.

The UIV 2020 Scientific Advisory Panel are calling for abstracts for both oral and poster presentation at the meeting. Abstracts should be sent directly to the UIV 2020 Secretariat (John Herriot at Meetings Management to email address: jherriot@meetingsmgmt.u-net.com).

**SCIENTIFIC ADVISORY PANEL**

UIV 2020 Conference Chairman:
Sarah Gilbert (Jenner Institute, University of Oxford, Oxford, UK)
Ted Ross (University of Georgia, Athens, Georgia, USA)
Sean Tucker (VAXART Inc., South San Francisco, California, USA)
John Oxford (Queen Mary University of London, London, UK)
Rob Lambkin-Williams (Virology Consult, London, UK)
Christopher Chadwick (World Health Organization, Geneva, Switzerland)
Pamuk Bilsel (FluGen Inc., Madison, Wisconsin, USA)
Otmar Engelhardt (NIBSC, South Mimms, Potters Bar, UK)
Tobias Kamphuis (Janssen Vaccines, Leiden, The Netherlands)
Anke Huckriede (University of Groningen, Groningen, The Netherlands)
Ron Babecoff (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Tamar Ben-Yedidia (BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel)
Harry Kleanthous (Gates Foundation, Seattle, Washington, USA)
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)
Emanuele Montomoli (VisMederi Srl, Siena, Italy)
Otfried Kistner (VisMederi, Siena, Italy)
Joanna Waldock (NIBSC, South Mimms, Potters Bar, UK)
Vivek Shinde (Novavax Inc, Rockeville, Maryland, USA)
Yuri Vasiliev (St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)
Shan Lu (University of Massachusetts, Worcester, Massachusetts, USA)
Welcome to Oxford & Opening Remarks
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

SESSION 1: OPENING PLENARY SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘A global perspective on universal influenza vaccines: What do we want and how will we use it?’
Christopher Chadwick, Martin Friede and Ann Moen
(World Health Organization, Geneva, Switzerland)

‘Scientific steps from the Spanish Influenza era have provided a firm foundation for both conventional and exploratory new influenza vaccines’
John S. Oxford and D. Gill
(Blizard Institute, Queen Mary College, London, UK)

‘Achieving better influenza vaccines: Implementation of NIAID’s strategic plan for universal influenza vaccine development’
Jennifer Gordon
(Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, HHS, Bethesda, Maryland, USA)

‘What is a Universal Influenza Vaccine? Is it possible?’
Rob Lambkin-Williams
(Virology Consult, London, UK)

Coffee Break & Poster Set-Up

SESSION 2: UNIVERSAL VACCINES

Moderator: John Oxford
(Blizard Institute, Queen Mary College, London, UK)

‘The development of a new approach to influenza vaccination, from concept to efficacy testing’
Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Development of a universal influenza vaccine technology landscape’
Julie Ostrowsky
(Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota, USA)

‘Development of universal influenza vaccines in Russia’
Yuri Vasilev
(St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

Lunch Break & Posters

SESSION 3: SUBTYPES/EPITOPES

Moderator: Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘From subtype coverage to universal flu vaccines’
Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘Utilising epitopes of limited variability to produce a broadly neutralising influenza vaccine’
Craig P. Thompson1,2, Uri Otolski1,2, Alex Fyfe1,2, Jose Lourenco1,2, Daniel O’Connor1, Teresa Lambe1, Christine Rollier1, Andrew Pollard1 and Sunetra Gupta1,2

‘Targeting highly conserved influenza A and B virus epitopes with nanoparticle-based vaccines’
David F. Zeigler, Emily Gage and Christopher H. Clegg
(TRIA Bioscience Corp, Seattle Washington, USA)

‘Permissive and preferential cell-lines for challenge agent and vaccine manufacture’
Adrian Wildfire
(SGS, Camberley, UK)

Tea Break & Posters

SESSION 4: STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION

Moderator: To be confirmed

‘Standardisation of serology assays used in the evaluation of vaccines’
Othmar G. Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Correlates of protection for influenza vaccines’
Emanuele Montomoli
(VisMederi SRL, Siena, Italy)
SESSION 5: IMMUNITY – I

Moderator: Ted M. Ross
(University of Georgia, Athens, Georgia, USA)

‘The art of measuring influenza-specific immunity’
Anke L.W. Huckriede
(University Medical Center Groningen, Groningen, The Netherlands)

‘Human T cell immunology of influenza’
Teresa Lambe
(University of Oxford, Oxford, UK)

‘Novel immune correlates of protection against influenza infection’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

‘Immune response profile induced by live M2SR (M2-deficient single replication) influenza vaccine and protection against human challenge with a substantially drifted H3N2 strain’
Joseph Eiden1, Bram Volckaert2, Oleg Rudenko2, Ruth Ellis3, Roger Aitchison3, Renee Herber3, Lawrence Moulton1, Dan Hoft4, David Marshall1 and Pamuk Bilsel1
(1 FluGen, Inc., Madison, Wisconsin, USA; 2 SGS Life Sciences, Antwerp, Belgium; 3 Biologics Consulting, Alexandria, Virginia, USA; 4 North Rim Consulting, Denver, Colorado, USA; 5 Johns Hopkins University, Baltimore, Maryland, USA; 6 Saint Louis University, St. Louis, Missouri, USA)

Coffee Break & Posters

SESSION 6: IMMUNITY

Moderator: Rob-Lambkin Williams
(Virology Consult, London, UK)

‘Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 protects ferrets and mice against influenza virus challenge’
(1 The Jenner Institute, University of Oxford, Oxford, United Kingdom; 2 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 3 Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4 Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 5 Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria)

‘Using pseudotypes for immunogenicity testing of universal influenza vaccines’
Nigel J. Temperton
(Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK)

‘Repeat vaccination reduces antibody affinity maturation irrespective of influenza vaccine drift platform in humans’
SURENDER KHURANA1, MEGAN HABRI1, ELIZABETH M. COYLE1, LISA R. KING1, TSAI-LIEN LIN1, JOHN TREANOR1, ANDREA SANT2 AND HANNA GOLDBERG1
(1 Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 2 Division of Biostatistics, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, Maryland, USA; 3 University of Rochester Medical Center, Rochester, New York, USA)

‘The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic inflammation and cytotoxicity in mice’
LI SONG1,2,3,4, XIANG KONG1,2,3,4, YANG JIAO1,2,3,4, XIAOHUI ZHOU1,2,3,4,5, KAIYUE WU1,2,3,4, YI ZHOU1,2,3,4, XIAN JIAO1,2,3,4, and ZHIMING PAN1,2,3,4
(1 Jiangsu Key Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Jiangsu, China; 2 Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu, China; 3 Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, Jiangsu, China; 4 Joint International Research Laboratory of Agriculture and Agri-product Safety of the Ministry of Education, Yangzhou University, Yangzhou, Jiangsu, China; 5 ePathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, Connecticut, USA)

Lunch Break & Posters

SESSION 7: VACCINES – I

Moderator: Yuri Vasiliev (St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation)

‘Evaluation of exploratory cellular and humoral responses to FLU-v, a universal influenza peptide vaccine tested in a clinical phase lb trial’
F. Oftung1, L.M. Nannis2, D. B. -Brattle1, I. Laake1, E. James1, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health, (NIPH) Norway; 2 PepTcell Ltd trading as SEEK, London, UK)

‘Next Generation H2 COBRA Hemagglutinin Vaccines Elicit Broadly Protective Antibodies Against H2N1 Influenza Viruses’
Z. Beau Reneer1, Parker J. Jameson and Ted M. Ross1,2
(1 Center for Vaccines and Immunology; 2 Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA)

‘Intranasal immunization with Nanovax-h5s vaccine (Nanovaxh5-NE01) induced Non-HAI antibodies that protected ferrets against a lethal heterologous clade of pandemic H5 flu challenge’
Ali Fattom
(Bluewillow Biologics. Ann Arbor, Michigan, USA)

‘Development of a broadly-protective M2e-based universal live attenuated influenza vaccine’
Irina Isakova-Sivak, Daria Mezhenskaya, Tatiana Kotomina, Victoria Matyushenko, Anastasia Evisina, Polina Prokopenko and Larisa Rudenko
(Institute of Experimental Medicine, St. Petersburg, Russia)

Tea Break & Posters

SESSION 8: MODELS

Moderator: Shan Lu
(University of Massachusetts, Worcester, Massachusetts, USA)

‘The pig influenza challenge model’
Elma Tchilian
(The PfizerBIO Institute, Pitright, Surrey, UK)

‘The intratracheal ferret challenge model to demonstrate effectiveness of Live attenuated, adjuvanted whole inactivated and split virus vaccines in preventing severe pneumonia induced by avian influenza’
Jargen de Jonge1, Harry van Dijken1, Sanne Spijkerts1, Justin Mouthaan1, Femke de Heij1, Rinke de Jong2, Paul Roholl3, Irina Isakova-Sivak4, Paulo Lee Ho5, Nicolas Colin6, Karen Smith-Korsholm7 and Larisa Rudenko8
(1 Centre for Infectious Disease Control, RIVM, Bilthoven, The Netherlands; 2 Central Veterinary Institute of Wageningen UR, Lelystad, The Netherlands; 3 Veterinary Microscope Consultancy, Weesp, The Netherlands; 4 Institute of Experimental Medicine, St. Petersburg, Russia; 5 Butantan, Sao Paulo, Brazil; 6 University of Lausanne (UNIL), Lausanne, France; 7 Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark)

‘In vitro assay and animal models for evaluation of Safety and Efficacy of next generation influenza vaccines and therapeutic antibodies’
Juanjie Tang, Laura Klenever, Hana Golding and Surender Khurana
(Division of Viral products, Center for Biologics Evaluation and Research, FDA, Silver Spring Maryland, USA)
SESSION 9: VACCINES – II

Moderator: Othmar Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Phase 3 results of quadrivalent nanoparticle influenza (Nanoflu) with Matrix-M™ adjuvant in adults 65 and older’
Vivek Shinde, Ikaung Cho, Lou Fries, Jamie Fiske and Greg Glenn
(Novavax Inc., Gaithersburg, Maryland, USA)

‘OVX836, a novel universal influenza vaccine candidate: Short-term results of a phase i clinical trial in humans’
K. Withanage1, P. Van Damme1, A. LeVert2, S. Viviani2, P. Willems2 and F. Nicolas2
(1 University of Antwerp, Belgium; 2 Osivax, Lyon, France)

‘Development of T cell-targeted universal influenza vaccines’
Christopher S. Eickhoff1, Frances E. Terry2, Krystal A. Meza1, Lenny Moise2,3, Anne S. De Groot1,4 and Daniel F. Hoft1,4
(1 Saint Louis University, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine and Infectious Disease, Saint Louis, Missouri, USA; 2 EpiVax, Inc., Providence, Rhode Island, USA; 3 University of Rhode Island; Institute for Immunology and Informatics, Providence, Rhode Island, USA)

‘Single-replication intranasal BM2SR vaccine provides cross-lineage protection against influenza B virus’
Pamuk Bilsel1, Mike Mosen2, David Marshall1, Yasuko Hatta1 and Sally Sarawar2
(1 FluGen, Inc. Madison, Wisconsin, USA; 2 BRISC, San Diego, California, USA)

Coffee Break & Posters

SESSION 10: PANEL DISCUSSION

Panel Discussion:
‘The elusive universal influenza vaccine: The way forward’
Moderator: To Be Confirmed

Lunch Break & Posters Breakdown

SESSION 11: LATEBREAKER SESSION

Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Harnessing the clec9a-targeting strategy to boost the immunogenicity of the universal flu antigen vaccine candidate M2e’
Ranmali Kavishna1, Mireille Lahoud2 and Sylvie Alonso1
(1 Department of Microbiology & Immunology, Yong Loo Lin School of Medicine; and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia)

‘Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets’
K. van de Ven, H. van Dijken, F. de Heij and J. de Jonge
(Centre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands)

‘Universal vector influenza vaccines: Pre-clinical research’
Igor Krasilnikov1, Ludmila Tzibalova2 and Marina Stukova3
(1 Saint-Petersburg Institute of Vaccines and Sera, FMBA Russia, St-Petersburg, Russia; 2 Smorodintsev Research Institute of Influenza, St-Petersburg, Russia)

‘SEC meets TRPS: Automated isolation and high-precision analysis of extracellular vesicles and viruses’
Camille Roesch1, Anoop K. Pai2, Shayne Harrel3, Robert Vogel2 and Murray Broom2
(1 Izon Science Europe Ltd, Lyon, France; 2 Izon Science Ltd, Medford, Massachusetts, USA; 3 Izon Science Ltd, Christchurch, New Zealand)

‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’
Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

Latebreaker abstracts for oral presentation at UIV 2020 are called for. Authors interested in submitting latebreaker oral abstracts should submit their abstracts directly to John Herriot at Meetings Management (UIV 2020 Organizers).

Please email your latebreaker abstracts to jherriot@meetingsmgmt.u-net.com

Closing date for latebreaker submissions is Friday 10th April 2020

POSTER SESSION

‘Evaluation of vaccine efficacy against Moroccan strain of LPAI H9N2 in experimental models in broiler chicken’
Yassmina Bidoudan
(Hassan II Veterinary and Agronomy Institute, Morocco)

‘Evaluation of exploratory cellular and humoral responses to FLU-v, a universal influenza peptide vaccine tested in a clinical phase Ib trial’
F. Oftung1, L.M. Naess1, D.B.-Bratlie1, I. Laake1, E. James2, G. Stoloff2 and O. Pleguezuelos2
(1 Infection Control and Environmental Health, Norwegian Institute of Public Health (NIPH), Norway; 2 PepTcell Ltd (trading as SEEK), London, UK)

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.
REGISTRATION

Delegates should register for UIV 2020 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (in £ Pounds Sterling) should be sent to the UIV 2020 Conference Manager – Caroline Sumner at Meetings Management. The UIV 2020 Conference Registration Desk will be open from 7.30am on Wednesday 29th April 2020.

Delegates can also register securely on-line at:
http://www.meetingsmanagement.com/uiv_2020

VENUE & ACCOMMODATION

The venue for UIV 2020 is the University of Oxford, Oxford, United Kingdom.

RICHARD DOLL BUILDING
University of Oxford, Old Road Campus, Oxford OX3 7LF, United Kingdom

There are numerous hotels in Oxford to suit most budgets. For information and details on local accommodation in Oxford convenient for the venue, please visit the UIV 2020 website and view the accommodation section for details:
http://www.meetingsmanagement.com/uiv_2020

April and May are busy times in Oxford and it is recommended that UIV 2020 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £2400.00 (£2000.00+20% VAT). If you do not wish to attend the conference sessions, you can reserve a table for £4800.00 (£4000.00+20% VAT) (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the UIV 2020 delegate pack is priced at £540.00 (£450.00+20% VAT). Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at UIV 2020 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to UIV 2020 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at UIV 2020. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The UIV 2020 Scientific Advisory Panel and the UIV 2020 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization’s library up to date. The cost of providing this non-attendee package is £474.00 (£395.00+20% VAT) (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, UIV 2020 Conference Manager:

UIV 2020 Conference Secretariat, Meetings Management
Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom.

Telephone: +44 (0)1483 427770
E-mail: csumer@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 10th April 2020. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 10th April 2020.
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname ................................................................. First Name ................................................................. Title .................................................................
Organization ................................................................................................................................. Address .................................................................
................................................................................................................................. Postcode .................................................................
Country ............ Telephone ................................................................. Fax .................................................................

E-mail (plain type or print): .................................................................................................................................

If you are an EC business please state your VAT registration number: .................................................................

Disabled (please state any special needs): ................................................................. Special diet (please state requirements): .................................................................

REGISTRATION FEES

Speaker/Delegate Registration Fees: (NOTE THAT FEES ARE IN UK £ STERLING) DELEGATE REGISTRATION FORMS NOT DULY & FULLY COMPLETED WILL NOT BE VALID

Amount Due (£ Sterling)

□ Speaker Registration (submitted oral/poster papers) £780.00 (£650.00+20% VAT) £

□ Reduced Early Bird Registration (Payment must be received before Friday 21st February 2020) £930.00 (£775.00+20% VAT) £

□ Full Registration (Payment received after Friday 21st February 2020) £1050.00 (£875.00+20% VAT) £

□ Student Registration Price on application £

Table Top Exhibits/Delegate Pack Inserts

□ Table Top Exhibit (I am registered to attend) £2400.00 (£2000.00+20% VAT) £

□ Table Top Exhibit (I am NOT registered to attend) £4800.00 (£4000.00+20% VAT) £

PLEASE NOTE: The above payments for Table Top Exhibits are for 1 company representative only. If you require additional representatives please contact the Conference Manager for a price.

□ Delegate Pack Insert £540.00 (£450.00+20% VAT) £

For those Unable to Attend

□ Set(s) of UIV 2020 materials @ £474.00 (per set) (£395.00+20% VAT) £

Total Amount Payable £

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 29th and 30th April and 1st May 2020.

PAYMENT

□ I enclose a cheque for £................................................................. made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote UIV 2020 on the reverse of the cheque.)

□ I have made a payment by bank transfer (quoting UIV 2020 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:


All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 3RD APRIL 2020. LATE PAYMENT AFTER FRIDAY 3RD APRIL 2020 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).

□ I would like to pay £................................................................. by credit card (VISA/MasterCard/American Express only accepted).

Card no. ................................................................. 3 Digit Security Code (AMEX: 4 Digits) .................................................................

Expiry Date ................................................................. Registered Card Address .................................................................

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 6th March 2020 will be refunded in full less an administrative charge of £275 per person. Refunds will not be possible if a cancellation is received after Friday 6th March 2020. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees. Delegates should be aware that Meetings Management reserve the right to postpone/rearrange the event if prevailing circumstances dictate such a course of action by the organisers. The event organisers will not be liable to delegates to the extent that any loss or failure that is caused by a force majeure event. Such an event would mean any cause beyond the organisers reasonable control.

VAT No. GB-591 6176 18

Signature ................................................................................................................................. Date .................................................................

PLEASE RETURN THIS FORM TO:

UIV 2020 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 E-mail: csumner@meetingsmgmt.u-net.com

SECURE ON-LINE REGISTRATION IS NOW OPEN AT: www.meetingsmanagement.com/uiv_2020